Success Metrics

Active Trials
1(25%)

Phase Distribution

Ph phase_2
1
25%
Ph phase_3
1
25%
Ph phase_4
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Other(2)

Detailed Status

unknown2
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 31 (33.3%)
Phase 41 (33.3%)

Trials by Status

not_yet_recruiting125%
unknown250%
recruiting125%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_3

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

NCT05566795
not_yet_recruitingphase_2

Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07408609
unknown

ctDNA as a Biomarker for Treatment in Advanced NSCLC

NCT05486988
unknownphase_4

Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer

NCT03799679

Clinical Trials (4)

Showing 4 of 4 trials
NCT05566795Phase 3

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Recruiting
NCT07408609Phase 2

Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Not Yet Recruiting
NCT05486988

ctDNA as a Biomarker for Treatment in Advanced NSCLC

Unknown
NCT03799679Phase 4

Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4